Scandion Oncology AS (OSTO:SCOL) Total Stockholders Equity : kr12.75 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology AS Total Stockholders Equity?

Scandion Oncology AS's Total Stockholders Equity for the quarter that ended in Dec. 2024 was kr12.75 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Scandion Oncology AS's Book Value per Share for the quarter that ended in Dec. 2024 was kr0.05. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Scandion Oncology AS's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.01.

Scandion Oncology AS Total Stockholders Equity Historical Data

The historical data trend for Scandion Oncology AS's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology AS Total Stockholders Equity Chart

Scandion Oncology AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

213.16

144.39

103.93

46.71

12.75

Scandion Oncology AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															46.71	35.75	46.47	36.09	12.75

Scandion Oncology AS (OSTO:SCOL) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Scandion Oncology AS's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(12.752	-	0)	/	234.762
	=	0.05

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Scandion Oncology AS's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.102	+	0)	/	12.752
	=	0.01

Scandion Oncology AS Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Scandion Oncology AS's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Scandion Oncology AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology AS (OSTO:SCOL) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

8VY:Germany

Address

Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100

Website

https://www.scandiononcology.com

Scandion Oncology AS is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options. The company's pipeline includes products like COROST for Colorectal Cancer, PANTAX for Pancreatic Cancer, 101 for other cancer indiction, 201 for Solid Tumors.

Scandion Oncology AS Headlines

No Headlines